Boston Scientific stock in focus as Stifel analyzes electrophysiology data ahead of investor day

Boston Scientific (BSX) is drawing investor attention ahead of its September 30 investor day, where its electrophysiology (EP) market strategy and innovation pipeline will be key topics. Recent Q3 2025 EP purchasing data, analyzed by Stifel, indicated strong double-digit growth in July followed by expected seasonal softness in August, with September data critical for the full quarter's performance. Concurrently, the company is executing strategic acquisitions, including the $88 million purchase of Elutia Inc.’s bioenvelope products, and preparing for the late 2025 launch of Bolt Medical’s intravascular lithotripsy system, driving positive analyst sentiment with Oppenheimer upgrading BSX to Outperform with a $125 price target, citing strong M&A and EP franchise execution.

Analysis

Boston Scientific (BSX) is exhibiting strong operational and strategic momentum, underscored by 21.44% revenue growth over the last twelve months and positive analyst actions. Recent electrophysiology (EP) purchasing data from Stifel for the third quarter of 2025 indicates a strong, double-digit start in July, followed by an expected seasonal slowdown in August, placing significant emphasis on the forthcoming September data to clarify the full quarter's performance. This data provides a crucial backdrop for the company's investor day on September 30, where management is expected to detail its EP market strategy and pulse-field-ablation (PFA) innovation pipeline. Reinforcing this growth narrative is a disciplined M&A strategy, evidenced by the definitive $88 million agreement to acquire Elutia Inc.'s bioenvelope products and the recent acquisition of Bolt Medical. The Bolt deal is set to introduce a new laser-based intravascular lithotripsy system in late 2025. This combination of organic trends and strategic acquisitions has prompted favorable analyst ratings, including an upgrade to 'Outperform' from Oppenheimer with a $125.00 price target, citing strong execution in both M&A and the core electrophysiology franchise.

Key Decisions for Investors

• Investors should closely monitor Boston Scientific's investor day on September 30 for pivotal updates on its electrophysiology strategy and innovation pipeline, which will be key to validating the current bullish thesis.
• The company's disciplined M&A strategy, including the Elutia and Bolt Medical acquisitions, should be assessed as a primary driver of future growth, with the planned late-2025 launch of Bolt's lithotripsy system serving as a key milestone to track.
• While analyst sentiment is strongly positive, as reflected by Oppenheimer's upgrade and $125 price target, it is prudent to await the complete Q3 electrophysiology purchasing data, including September's results, to fully confirm the growth trajectory.